… the question of inflammation-guided therapy for cardiovascular risk prevention [44]. The
trial investigated whether statin therapy might affect cardiovascular risk in subjects with LDL …

… an increased atherosclerotic risk which cannot be explained by traditional cardiovascular
risk factors alone. Inflammatory pathways are implicated in this increased vascular risk. The …

… III for very high-risk patients, as HDL-C progressively decreases, risk for cardiovascular
events increases. Is simply driving LDL lower enough to optimize cardiovascular risk reduction? …

… in cardiac disorders treatment. The emphasis of this review will be on bringing recent
development in cardiac disorders from the discoveries of drug targets and their ligands. …

… from cardiac disease. In 2010 the first analyses of the Action to Control Cardiovascular Risk
in … did not further increase the risk of cardiovascular events in type 2 diabetic patients at high …

… therapies, questioning the safety of this approach. Therefore, to safely control thrombosis risk
… with the fibrin network representing a credible therapeutic target. In the current review, we …

… cardiovascular events and worse prognosis in patients with CVD [9-13]. Curiously, they
might be important therapeutic targets … cholesterol are key therapeutic targets implemented to …

… Thus, NF-κB is a potential therapeutic target in the treatment of atherosclerosis and related
CVDs. Several biologics and small molecules as well as peptide/proteins have been shown …

… biomarkers may facilitate individualized drug treatment and provide new therapeutic targets.
… conventional risk factors. Nonetheless, they may offer exciting new therapeutic targets, as …

… for weight and other risk factors (17, 18). Furthermore, the magnitude of cardiovascular risk
associated with CRP is similar in magnitude to that of traditional risk factors including systolic …